BRAIN and NERVE－神経研究の進歩70巻1号

2018年01月発行

総説

アルツハイマー病診断におけるSNAPとその背景疾患

著者： 山田正仁¹

所属機関： ¹金沢大学大学院医薬保健学総合研究科医学専攻脳老化・神経病態学（神経内科学）

ページ範囲：P.59 - P.71

文献概要

SNAP（suspected non-Alzheimer's disease pathophysiology）はバイオマーカーに基づく概念で，バイオマーカー（PETや脳脊髄液マーカー）でアミロイドβ蛋白は正常レベルでありながらアルツハイマー病（AD）様の神経変性を示す病態である。SNAPは認知機能健常高齢者や軽度認知障害やAD認知症の臨床診断例の2〜3割前後を占める。SNAPの進行はADより遅い。その背景疾患は多様で非ADタウオパチーが含まれる。

参考文献

1)Jack CR Jr, Albert MS, Knopman DS, McKhann GM, Sperling RA, et al: Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 257-262, 2011

2)McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, et al: The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 263-269, 2011

3)Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, et al: The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 270-279, 2011

4)Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, et al: Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 280-292, 2011

5)Jack CR Jr, Knopman DS, Weigand SD, Wiste HJ, Vemuri P, et al: An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol 71: 765-775, 2012

6)Jack CR Jr, Knopman DS, Chételat G, Dickson D, Fagan AM, et al: Suspected non-Alzheimer disease pathophysiology-concept and controversy. Nat Rev Neurol 12: 117-124, 2016

7)Vos SJ, Verhey F, Frölich L, Kornhuber J, Wiltfang J, et al: Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Brain 138: 1327-1338, 2015

8)Landau SM, Horng A, Fero A, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative: Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI. Neurology 86: 1377-1385, 2016

9)Jack CR Jr, Wiste HJ, Weigand SD, Therneau TM, Knopman DS, et al: Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study. Lancet Neurol 16: 435-444, 2017

10)Knopman DS, Jack CR Jr, Wiste HJ, Weigand SD, Vemuri P, et al: Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology 78: 1576-1582, 2012

11)Vos SJ, Xiong C, Visser PJ, Jasielec MS, Hassenstab J, et al: Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol 12: 957-965, 2013

12)van Harten AC, Smits LL, Teunissen CE, Visser PJ, Koene T, et al: Preclinical AD predicts decline in memory and executive functions in subjective complaints. Neurology 81: 1409-1416, 2013

13)Wirth M, Villeneuve S, Haase CM, Madison CM, Oh H, et al: Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. JAMA Neurol 70: 1512-1519, 2013

14)Toledo JB, Weiner MW, Wolk DA, Da X, Chen K, et al: Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition. Acta Neuropathol Commun 2: 26, 2014［doi: 10.1186/2051-5960-2-26］

15)Mormino EC, Betensky RA, Hedden T, Schultz AP, Amariglio RE, et al: Synergistic effect of β-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol 71: 1379-1385, 2014

16)Soldan A, Pettigrew C, Cai Q, Wang MC, Moghekar AR, et al: Hypothetical preclinical Alzheimer disease groups and longitudinal cognitive change. JAMA Neurol 73: 698-705, 2016

17)Mormino EC, Papp KV, Rentz DM, Schultz AP, LaPoint M, et al: Heterogeneity in suspected non-Alzheimer disease pathophysiology among clinically normal older individuals. JAMA Neurol 73: 1185-1191, 2016

18)Gordon BA, Blazey T, Su Y, Fagan AM, Holtzman DM, et al: Longitudinal β-amyloid deposition and hippocampal volume in preclinical Alzheimer disease and suspected non-Alzheimer disease pathophysiology. JAMA Neurol 73: 1192-1200, 2016

19)Burnham SC, Bourgeat P, Doré V, Savage G, Brown B,et al: Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study. Lancet Neurol 15: 1044-1053, 2016

20)Schreiber S, Schreiber F, Lockhart SN, Horng A, Bejanin A, et al: Alzheimer disease signature neurodegeneration and APOE genotype in mild cognitive impairment with suspected non-Alzheimer disease pathophysiology. JAMA Neurol 74: 650-659, 2017

21)Knopman DS, Jack CR Jr, Wiste HJ, Weigand SD, Vemuri P, et al: Brain injury biomarkers are not dependent on β-amyloid in normal elderly. Ann Neurol 73: 472-480, 2013

22)Prestia A, Caroli A, van der Flier WM, Ossenkoppele R, Van Berckel B, et al: Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology 80: 1048-1056, 2013

F-flutemetamol and structural magnetic resonance imaging in the classification of mild cognitive impairment and Alzheimer's disease. Alzheimers Dement 9: 295-301, 2013

24)Petersen RC, Aisen P, Boeve BF, Geda YE, Ivnik RJ, et al: Mild cognitive impairment due to Alzheimer disease in the community. Ann Neurol 74: 199-208, 2013

25)Caroli A, Prestia A, Galluzzi S, Ferrari C, van der Flier WM, et al: Mild cognitive impairment with suspected nonamyloid pathology (SNAP): prediction of progression. Neurology 84: 508-515, 2015

26)Wisse LEM, Butala N, Das SR, Davatzikos C, Dickerson BC, et al: Suspected non-AD pathology in mild cognitive impairment. Neurobiol Aging 36: 3152-3162, 2015

27)Knopman DS, Jack CR Jr, Lundt ES, Wiste HJ, Weigand SD, et al: Role of β-amyloidosis and neurodegeneration in subsequent imaging changes in mild cognitive impairment. JAMA Neurol 72: 1475-1483, 2015

28)Chung JK, Plitman E, Nakajima S, Caravaggio F, Iwata Y, et al: Hippocampal and clinical trajectories of mild cognitive impairment with suspected non-Alzheimer's disease pathology. J Alzheimers Dis 58: 747-762, 2017

29)Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, et al: Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56: 303-308, 1999

30)Petersen RC: Mild cognitive impairment as a diagnostic entity. J Intern Med 256: 183-194, 2004

31)Ossenkoppele R, Prins ND, Pijnenburg YA, Lemstra AW, van der Flier WM, et al: Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimers Dement 9: 414-421, 2013

32)Sánchez-Juan P, Ghosh PM, Hagen J, Gesierich B, Henry M, et al: Practical utility of amyloid and FDG-PET in an academic dementia center. Neurology 82: 230-238, 2014

33)Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, et al: Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 370: 322-333, 2014

34)Lowe VJ, Peller PJ, Weigand SD, Montoya Quintero C, Tosakulwong N, et al: Application of the National Institute on Aging-Alzheimer's Association AD criteria to ADNI. Neurology 80: 2130-2137, 2013

35)Abner EL, Kryscio RJ, Schmitt FA, Fardo DW, Moga DC, et al: Outcomes after diagnosis of mild cognitive impairment in a large autopsy series. Ann Neurol 81: 549-559, 2017

36)Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF, Abner EL, et al: Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol 128: 755-766, 2014

37)Braak H, Braak E: Argyrophilic grains: characteristic pathology of cerebral cortex in cases of adult onset dementia without Alzheimer changes. Neurosci Lett 76: 124-127, 1987

38)Saito Y, Nakahara K, Yamanouchi H, Murayama S: Severe involvement of ambient gyrus in dementia with grains. J Neuropathol Exp Neurol 61: 789-796, 2002

39)Saito Y, Ruberu NN, Sawabe M, Arai T, Tanaka N, et al: Staging of argyrophilic grains: an age-associated tauopathy. J Neuropathol Exp Neurol 63: 911-918, 2004

40)Adachi T, Saito Y, Hatsuta H, Funabe S, Tokumaru AM, et al: Neuropathological asymmetry in argyrophilic grain disease. J Neuropathol Exp Neurol 69: 737-744, 2010

41)Yamada M, Itoh Y, Otomo E, Suematsu N, Matsushita M: Dementia of the Alzheimer type and related dementias in the aged: DAT subgroups and senile dementia of the neurofibrillary tangle type. Neuropathology 16: 89-98, 1996

42)山田正仁：Senile dementia of the neurofibrillary tangle type（SD-NFT）とPrimary age-related tauopathy（PART）の概念をめぐって. Dementia Japan 30: 103-111, 2016

43)Matsui Y, Tanizaki Y, Arima H, Yonemoto K, Doi Y, et al: Incidence and survival of dementia in a general population of Japanese elderly: the Hisayama study. J Neurol Neurosurg Psychiatry 80: 366-370, 2009

44)Honda H, Sasaki K, Hamasaki H, Shijo M, Koyama S, et al: Trends in autopsy-verified dementia prevalence over 29 years of the Hisayama study. Neuropathology 36: 383-387, 2016

45)Yamada M, Itoh Y, Sodeyama N, Suematsu N, Otomo E, et al: Senile dementia of the neurofibrillary tangle type: a comparison with Alzheimer's disease. Dement Geriatr Cogn Disord 12: 117-126, 2001

46)Yamada M, Itoh Y, Sodeyama N, Suematsu N, Otomo E, et al: Aging of the human limbic system: observations of centenarian brains and analyses of genetic risk factors for senile changes. Neuropathology 18: 228-234, 1998

47)Yamada M: Senile dementia of the neurofibrillary tangle type (tangle-only dementia): neuropathological criteria and clinical guidelines for diagnosis. Neuropathology 23: 311-317, 2003

48)Josephs KA, Murray ME, Tosakulwong N, Whitwell JL, Knopman DS, et al: Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART). Acta Neuropathol 133: 705-715, 2017

49)Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, et al: Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 367: 795-804, 2012

50)Braak H, Braak E: Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82: 239-259, 1991

51)Schöll M, Lockhart SN, Schonhaut DR, O'Neil JP, Janabi M, et al: PET imaging of tau deposition in the aging human brain. Neuron 89: 971-982, 2016

F-AV-1451 recapitulate key features of Braak histopathological stages. Brain 139: 1539-1550, 2016

53)Sperling R, Mormino E, Johnson K: The evolution of preclinical Alzheimer's disease: implications for prevention trials. Neuron 84: 608-622, 2014